I am delighted to share an update on the strong performance of Evergrowth BioHealthcare Capital. Since inception, the fund has delivered gross returns exceeding 83%, and year-to-date through December 2025, we have achieved gross returns over 24%. These outstanding results reflect the disciplined and research-driven strategy. As Christmas and the New Year draw near, my...
As a physician-turned-investor managing a biotech hedge fund, I’ve watched many smart colleagues (and investors in general) dive into the exciting world of stock charts. Patterns like “head and shoulders,” moving averages, or RSI indicators can feel sophisticated—especially with multiple screens lighting up your desk. When my daughter Hannah was a baby singing “Head, Shoulders,...
Dear Fellow Physicians, You’ve heard the timeless investing mantra: “Buy low, sell high.” It’s deceptively simple—yet most investors, even highly trained professionals like you, end up doing precisely the opposite. Why? Because fear is the most powerful emotion in markets.When a stock (or an entire sector) is spiraling lower, fear screams that it will go...
It is with great pleasure that we welcome Dr. Victoria Mondloch to Evergrowth’s Medical and Scientific Advisory Board. Dr. Mondloch is a distinguished OB/GYN physician, consultant, and author, bringing decades of clinical and advisory experience to the table. We are incredibly fortunate to have her insights and leadership as we continue to grow Evergrowth’s biotech...